Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy

BACKGROUND—: Current therapies are ineffective in preventing the development of cardiac phenotype in young carriers of mutations associated with hypertrophic cardiomyopathy (HCM). Ranolazine, a late Na(+) current blocker, reduced the electromechanical dysfunction of human HCM myocardium in vitro. ME...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Circ Heart Fail
Egile Nagusiak: Coppini, Raffaele, Mazzoni, Luca, Ferrantini, Cecilia, Gentile, Francesca, Pioner, Josè Manuel, Laurino, Annunziatina, Santini, Lorenzo, Bargelli, Valentina, Rotellini, Matteo, Bartolucci, Gianluca, Crocini, Claudia, Sacconi, Leonardo, Tesi, Chiara, Belardinelli, Luiz, Tardiff, Jil, Mugelli, Alessandro, Olivotto, Iacopo, Cerbai, Elisabetta, Poggesi, Corrado
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6284403/
https://ncbi.nlm.nih.gov/pubmed/28255011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCHEARTFAILURE.116.003565
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak